How Otarmeni’s approval reveals inconsistencies in the process
“Today’s approval is a significant milestone in the treatment of genetic hearing loss,” announced the Food and Drug Administration (FDA) commissioner Marty Makary during a speech. On April 23, 2026, the FDA approved Otarmeni, the first-ever gene therapy developed by biotechnology company Regeneron to treat genetic hearing loss. The treatment was approved through the Commissioner’s National Priority Voucher (CNPV) pilot program, one of the FDA’s new accelerated approval pathways for products aligned with national health priorities. Otarmeni represents a significant breakthrough in otolaryngology, an area of medicine that is often overlooked by scientists. The therapy treats adults and children born with severe hearing loss due to biallelic mutations in the OTOF gene. The gene encodes otoferlin, a protein expressed in the inner hair cells of the cochlea, and is responsible for converting sound wave vibrations into electrical signals. The company has also decided to make the treatment free for all US patients. Ultimately, while programs such as Fast Track and CNPV expedite the process of drug approvals for life-saving diseases and conditions, they overlook weak points in the clinical data, which can be risky in approving new technologies in a short amount of time.
New therapies and medications are typically approved through the FDA in an arduous process that involves initial research, followed by animal testing and multiple phases of human clinical trials. From start to finish, the process can take between ten and fifteen years, and only a small percentage of drugs that begin development are approved. In special cases, the FDA offers expedited approval for innovative drugs that address health crises or immediate public health needs through programs like Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval. In this case, Otarmeni was the first treatment to be approved by the FDA through the Commissioner’s National Priority Voucher (CNPV) pilot program, announced in June 2025. The program approved it in a mere sixty one days as opposed to the several years that the typical process takes.
Some therapies and treatments approved through expedited review programs lack successful clinical trials, potentially putting patients at risk. A drug or new technology that doesn’t show successful clinical trials during the normal approval process can be scrapped entirely and forced to restart. However, accelerated approval pathways use lower regulatory standards and are often slow to withdraw studies without any confirmed benefit to patients, as they don’t require a successful clinical benefit before approval. The Office of Inspector General (OIG) found that out of 24 drugs reviewed by them, three had major concerns by the general public and by reviewers of the companies. Recently, in April 2026, anti-amyloid drugs approved by the FDA used to treat Alzheimer’s disease showed “no clinically meaningful effect,” according to lead researcher Dr. Francesco Nonino. The Phase I/II CHORD trial for Otarmeni showed that 80% of participants had hearing improvements twenty four weeks after treatment. Not only was the Alzheimer’s drug unsuccessful, but it also revealed gaps and mistakes that were ignored by the FDA’s expedited approval process. The normal approval process of the FDA, despite being a long process, accounts for these errors and identifies most of them before the product is approved. The lack of attention to detail by the FDA could harm the institution’s image, and worse, put the lives of millions of Americans in danger.
